The Patent Finder

Ucb Biopharma SRL

183 patents currently held · Updated Nov 15, 2026
14 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

Previously recorded as Ucb Biopharma SPRL (to 2020)

15
Ending by 2030
Oct 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Dec 4 to 13, 2026 · next Dec 4
  • 6 fees due Jan 4 to 25, 2027 · next Jan 4
  • 3 fees due Feb 6 to 22, 2027 · next Feb 6
  • 3 fees due Mar 5 to 24, 2027 · next Mar 5
  • 2 fees due Apr 17 to 29, 2027 · next Apr 17
  • 2 fees due May 5 to 19, 2027 · next May 5
  • 2 fees due Jun 3 to 5, 2027 · next Jun 3
  • 3 fees due Jul 2 to 30, 2027 · next Jul 2
  • 3 fees due Aug 18 to 27, 2027 · next Aug 18
  • 3 fees due Sep 5 to 26, 2027 · next Sep 5
  • 3 fees due Oct 14 to 21, 2027 · next Oct 14
  • 4 fees due Nov 5 to 10, 2027 · next Nov 5

Which patents, and when each one lapses · Pro

Recent changes

  • 5 of the patents on this record were granted since Aug 17, 2026
  • 5 terms have ended since Aug 17, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 9,890,219Methods of treating an IL-17A mediated pathological condition
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,308,723Method of treating inflammation by administering antibody molecules which bind IL-17A and IL-17F
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,784,823Binding Proteins, Including Antibodies, Antibody Derivatives and Antibody Fragments, That Specifically Bind CD154 and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 9,321,840Binding Proteins, Including Antibodies, Antibody Derivatives and Antibody Fragments, That Specifically Bind CD154 and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 8,338,592Fused thiazole derivatives as kinase inhibitors
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,183,2412-oxo-1-pyrrolidine derivatives
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,293,237Binding Proteins, Including Antibodies, Antibody Derivatives and Antibody Fragments, That Specifically Bind CD154 and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 9,901,686Systems and methods for administering medication
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,771,420Methods of treating an IL-17A mediated pathological condition
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,661,023Systems and methods for administering medication
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 183 patents shown.
Pro members see all 183.
Pro members: see all 183 patents
Also on record, not counted in the 183: 14 patents in force now held by others · 81 lapsed for an unpaid fee · 8 ended at full term · 1 surrendered on reissue. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

50 pending · 15 abandoned · 23 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited